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ABST RACT
Vesicants are compounds that cause severe toxic effects on various tissues. Such
chemical action causes tissue necrosis, with clinical expression of skin lesions
with a burning character and characteristic blisters. Clinical toxic effects of
cutaneous vesicles are correlated with the absorbed dose and exposure time. The
goals of the study are to evaluate in vitro the skin toxicity produced by the
vesicant chemical compound 2-chloroethyl-ethyl sulfide (CEES), to develop a
complex antidote formula, and to optimize the therapeutic efficacy by inclusion
in controlled release systems. The experimental protocol aims at the in vitro
evaluation of the cytotoxicity of the vesicant compound CEES and of the
optimized complex antidote, using the MTT cell viability test. Optimization of
the complex antidote formula was achieved by developing and in vitro and in
vivo testing of a fixed combination of active substances with anti-inflammatory
and antioxidant effects, formulated as a solution with cutaneous administration.
In vitro cytotoxicity tests on fibroblast cultures revealed the protective effect of
the newly developed antidote solution, specifically a dose-related effect in the
case of vesicant exposure.

Introduction
Vesicants are compounds that cause serious toxic
effects to the eyes, lungs and skin, either by direct contact
or through inhalation of vapors. This class of substances
includes mustard gas, mustard nitrogen, halogenated
oximes and arsenic agents [1,2]. Halogenated vesicants are
a family of compounds based on sulfur, nitrogen and
oxygen, with similar chemical and biological effects.
There are two types of mustard-based vesicants:
nitrogen mustards, known for their use as chemotherapy
drugs, and sulfur mustards, that are known only for their
applications as warfare agents [3]. When dermally
absorbed, molecules of sulfur-based vesicular compounds
cyclize forming a highly reactive intermediate that binds to
tissue proteins [4]. This chemical action causes tissue
necrosis, clinically manifested as burn-like skin lesions and
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characteristic phlyctenules (blisters). Basal epidermal
keratinocytes are the first target. After this, vesicant
compounds cause cell death (apoptosis), followed by
digestion of the anchoring filaments’ protease at the level
of dermal-epidermal junctions, which leads to separation
and the appearance of vesicles [5-7].
The present study performs an in vitro evaluation of
skin toxicity produced by the vesicant chemical compound,
2-chloroethyl-ethyl sulfide (CEES). The objectives of this
study are represented by the development of a complex
antidote formulation, which pharmacodynamically should
be able to antagonize the toxicity of vesicants. As a result
of this action, a possible remission of severe lesions is
expected, in order to delay the surgical procedure and thus
to optimize the therapeutic effectiveness by including it in
the systems with a possible controlled release (in the form
of microemulsions).
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Materials and Methods
Materials and reagents
The following materials and reagents were used to
perform the experimental study:
− MTT cell viability determination kit – SIGMA
ALDRICH Germany product;
− 2-chloroethyl-ethyl sulfur (CEES) 97% purity – Sigma
Aldrich Germany product;
− dexamethasone - CAS number 50-02-2 99% purity,
produced by Sigma-Aldrich Chemie GmbH, Germany;
− acetylcysteine - CAS number 616-91-1 99% purity,
product of MERCK, Germany;
− nicotinamide mononucleotide CAS number 1094-61-7
95% purity produced by Sigma Aldrich, Germany;
− hydrolyzed hyaluronic acid - CAS number 9004-61-9.
Purity ≥98%, produced by PARCHEM, USA;
− recombinant human epidermal growth factor,
expressed in E. coli, ≥98% packed as 0,1 mg, produced
by Alomone Laboratories, Israel;
− ketoprofen CAS number 22071-15-4 98% purity
produced by Sigma-Aldrich Chemie GmbH, Germany.
Laboratory equipment
EnSight™ Multimode Microplate Reader multimodal
reader, PERKIN ELMER, used for optical density reading
in the MTT method for determining cell viability;
− NANO ZETASIZER MALVERN PANALITICAL
standard cell analysis system, used for dynamic light
diffusion
measurements
in
the
study
of
microemulsions;
− HPLC LC 4500 JASCO INC system, used to determine
the analytical method for dosing antidote components
in solutions and microemulsions;
− ChromNAV 2.0 HPLC software.
The experimental design went through the following
stages:
Pharmaceutical formulation of the complex antidote
A complex formulation was prepared in the form of a
percutaneous solution whose active substances are capable
to pharmacodynamically antagonizing the toxicity of
the studied vesicant compound. The following composition
is studied: 10% acetylcysteine (antioxidant); 5% ketoprofen
(non-steroidal
antiinflammatory
compound);
4%
dexamethasone (steroidal antiinflammatory compound);
10% nicotinamide nucleotide (PARP inhibitor); epidermal
growth factor (EGF) 0,1 µg/mL (the stock solution dosage
form, 10 µg/ml in concentration, was prepared in 0.9% w/v
NaCl); PBS excipients ad 100 ml buffer containing
disodium phosphate, sodium chloride, potassium
phosphate and potassium chloride, achieving a pH of 7.8,
necessary for faster transdermal absorption.
Experimental protocol
In vitro evaluation of 2-chlorodiethyl-ethyl sulfide
(CEES) vesicant’s cytotoxicity and of the optimized
complex antidote, using the MTT cell viability test.

An experimental model for in vitro toxicity assessment
was performed by incubating a culture of fibroblasts (106
cells/ml) with doses of CEES 1: 7.78 × 10-2 M and CEES
2: 7.78 × 10-3M. The cell viability testing was performed
using the MTT kit and 3T3 fibroblast cell line.
The 3T3 fibroblast cell line was cultured in 25 cm2 cell
culture dishes using Dulbecco's Modified Eagle's Medium
(DMEM) supplemented with 10% fetal bovine serum
(FBS) and 50 μg/ml gentamicin.
Cells in a 25 cm2 dish were trypsinized with 0,025%
trypsin-EDTA and then centrifuged, while the pellet was
resuspended in 5 ml of complete DMEM medium. Initial cell
count was performed by Tripan Blue 1:1 staining (50 μl cell
suspension + 50 μl Tripan Blue). The cell suspension has a
concentration of 1.07 x 106 cells/ml.
To perform the cytotoxicity test, the cell suspension is
cultured in a 96-well flat-bottomed microplate of 200
μl/well (2.14 x 105 cells/well) and incubated in a CO2
incubator (5%) at 370 C, for 24 hours.
The next day, the medium is changed as follows:
− remove the medium from the control cell wells and add
200 μl of completely fresh DMEM medium;
− in the wells with CEES toxic control, remove the
medium and add 100 μl of fresh DMEM medium + 100
μl of CEES;
− the medium is removed from the wells containing
solutions to be tested and 100 μl of CEES + 100 μl of
test treatment solution in different concentrations
(dilutions) are added;
− only 200 μl of complete DMEM medium is added to
the blank wells; incubate the microplate in the CO2
incubator (5%) at 370 C, for 24 hours.
After 24 hours, the 3-(4,5-)dimethyl-2-thiazolyl-2,5diphenyl-2H-tetrazolium bromide (MTT) test is performed
to measure the conversion of MTT to a stained product in
living cells. For this test, we used the MTT-based cell
growth assay kit (Sigma) containing the MTT solution (5
mg/ml MTT in RPMI-1640 without phenol red) and the
MTT solvent (0.1 N HCl in anhydrous isopropanol).
Remove the microplate from the incubator, add 20 μl
MTT/well (10% of the medium’s volume) and proceed
with dark incubation for 4 hours, at 370C, in CO2. After 4
hours, remove the microplate from the incubator, remove
the medium and add the MTT solvent, 200 μl/well. Read
the optical density at a wavelength of 570 nm within one
hour of adding the solvent using the PerkinElmer
multimodal reader (EnSight™ Multimode Microplate
Reader).
Obtaining and characterizing a delivery and controlled
release system for the formulation of a chemical burn
antidote
Obtaining microemulsions as a nanostructured delivery
vector for antidote components. In order to control the
release of the active substances that were proposed for the
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formulation of the antidote, we suggested encapsulating
them in the aqueous phase of microemulsions prepared
from components with high biocompatibility. Skin
absorption during transdermal administration of drugs is
favored by the presence of surfactants that stabilize
microemulsions.
Preliminary tests were performed for the preparation of
uniphasic microemulsions with bicontinuous structure.
Thus, we selected a composition which leads to obtaining
bicontinuous structured Winsor IV microemulsion
systems: sample 4 composition: 32% aqueous phase; 33%
oil phase (IPM); 35% Surfactant-Cosurfactant (Tw80 +
Sp80). The surfactant/cosurfactant molar ratio that gave the
best results regarding the size of the microemulsion area on
the phase diagram was 1:1, thus being selected for the final
formula in the series. Dynamic light diffusion
measurements were performed using the undiluted
microemulsion, with a standard cell Nano Zetasizer
Malvern instrument. The mean size of the liquid droplets
was 19.54 ± 2.56 nm.
Establishment of the analytical dosing method for the
antidote components in solutions and microemulsions
In order to study the release of active substances from
the antidote formulations, we used the quantitative dosing
of the antiinflammatory components of the proposed
antidote preparation, namely dexamethasone and
ketoprofen (inflammation mediation through oxidative
stress being the main pathogenic mechanism involved in
skin toxicity of vesicants). Tests were performed using the
HPLC LC 4500 JASCO INC system. Chromatographic
data were obtained using the ChromNAV 2.0 HPLC
software.
Study of the release profile of antidote components
To evaluate the release profile of the antidote’s
components during transdermal administration, a
permeability study was performed for the aqueous solution
and for the selected microemulsion, taking into
consideration it had the composition with the highest
biocompatibility, due to the characteristics of surfactants
used for stabilization. The in vitro permeation study was
performed using a Strat-M® membrane as a material that
mimics the properties of the skin and the Franz cell
technique. The in vitro skin permeability study using

ketoprofen and dexamethasone was performed using a
vertical Franz cell (PermeGear, Inc., Hellertown, PA,
USA). Each experiment was performed three times.
The effective diffusion area of the membrane mounted
on the Franz cell was 0.99 cm2. The 8 mL receptor
compartment was filled with medium consisting of
phosphate-buffered saline (PBS; pH 7.4). These
experimental conditions are considered to be sink, thus
assuming that the concentration of the drug in the receptor
solution is negligible compared to that in the donor
compartment. The diffusion cell was maintained at 37° C,
and the receptor compartment was continuously
homogenized using a magnetic stirrer. Then, 0.5 g of
aqueous or microemulsion was added to the donor system
compartment, which was sealed with Parafilm® to prevent
evaporation of the sample. After certain time intervals (0.5,
1, 2, 4, 6, 10 and 24 h), 0.5 mL samples were extracted
from the receptor medium and supplemented with a new
receptor medium to maintain a constant volume. Samples
of the analyte receptor medium extracted at said time
intervals were analyzed using the methods described
above, after appropriate prior dilution.

Results
In vitro evaluation of the cytotoxicity of the vesicant
compound 2-chlorodietylethyl sulfide (CEES) and of the
complex antidote optimized solution (A1), using the MTT
cell viability test.
The following formula is used to interpret the results:
% cell viability = (DO positive control – DO
blank)/(DO negative control – DO blank) x 100
Where:
DO = optical density read at 570 nm
positive control = cells + CEES and treatment + CEES
+ MTT + MTT solvent
negative control = cells + MTT + MTT solvent
blank = medium (complete DMEM) + MTT + MTT
solvent
Antidote treatment stock solution was formed by:
Acetylcysteine: 10%; Dexamethasone: 4%; Ketoprofen:
5%; 1/5 and 1/10 dilutions were prepared from the stock
antidote solution (Table 1).

Table 1. The distribution in wells on the cell culture plate
1

2

Blank

Cells
control

Blank

Cells
control

3

4

5

6

7

8

Cells + Cells+
Stock
CEES1
treatment

Cells+
CEES1

Cells+
CEES1+ stock
treatment

Cells+
CEES1+ stock
treatment

Cells+
CEES1+ 1/5
treatment

Cells+
Cells+
CEES1+ 1/5 CEES1+ 1/10
treatment
treatment

Cells+
CEES1+ 1/10
treatment

Cells+
Cells+
Stock
CEES2
treatment

Cells+
CEES2

Cells+
CEES2+ stock
treatment

Cells+
CEES2+ stock
treatment

Cells+
CEES2+ 1/5
treatment

Cells+
Cells+
CEES2+ 1/5 CEES2+ 1/10
treatment
treatment

Cells+
CEES2+ 1/10
treatment

The samples (positive control) were processed in 2
wells for each treatment concentration. At the end, the
296
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10

11

arithmetic mean of the optical densities readings read at a
wavelength of 570 nm was calculated. The negative control
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and the blank were distributed in duplicate, and the
arithmetic mean of the read optical densities was calculated
afterwards (Table 2). The average values of the cell

viability (calculated in percentages) and which are
determined by the tested compounds are represented in
Table 3, as well as in Figures 1 and 2.

Table 2. The average values of optical density (DO) at 570 nm
Toxic
CEES 1
CEES 2

1
0,054
±0,0037

2
1,578±
0,067

3
1,389±
0,049

4
5
0,064 ±0,002

6
7
0,823 ± 0,004

8
9
0,587± 0,0025

10
11
0,291± 0,001

0,070 ±0,0015

0,944 ± 0,0035

0,700± 0,0025

0,343± 0,003

Footnote. CEES 1: mean optical density (DO) values for cell exposure to CEES 1, concentration 7.78 × 10-2M; CEES 2: mean
optical density (DO) values for cell exposure to CEES 2, concentration 7.78 × 10-3M; Column 1 blank DO; Column 2 control
untreated cells DO; Column 3 cells + stock treatment;
Columns 4, 5 average DO values: CEES + cells; Columns 6, 7 average DO values: CEES + stock treatment + cells; Columns 8, 9
average DO values: CEES + 1/5 dilution stock treatment + cells; Columns 10, 11 average DO values: CEES + 1/10 dilution stock
treatment + cells

Table 3. Cell viability in different solutions
1
CEES 1
CEES 2

2

3

100

87,570±2,67

4

5

0,668 ±0,05
1,010±0,07

6

7

50,432 ± 0,49
50,387± 0,55

8

9

34,989 ± 0,89
42,384± 0,98

10

11

15,20± 0,9
18,980± 0,73

Footnote. CEES 1 mean cell viability values for cell exposure to CEES 1, concentration 7.78 × 10-2M
CEES 2 is the mean cell viability values for cell exposure to CEES 2, concentration 7.78 × 10-3M;
Column 2 was considered reference (100%) for the value of cell viability for control untreated cells; corresponding DO 1,578 ±
0,067; Column 3 cells + stock treatment; Columns 4, 5 average cell viability values: CEES + cells. Columns 6, 7 average cell
viability values: CEES + stock treatment + cells. Columns 8, 9 average cell viability values: CEES + 1/5 dilution stock treatment +
cells. Columns 10, 11 average cell viability values: CEES + 1/10 dilution stock treatment + cells

Figure 1. Cell viability after exposure to CEES-1
The CEES 2 formulation (concentration 7.78 * 10-3M)
showed a lower toxicity compared to CEES1 (concentration
7.78 * 10-2M). The 1/1 dilution treatment reduced cytotoxicity of the toxic compound for both CEES formulations.
The reduction of the treatment effect with the increase of its
dilution (1/5 and 1/10 respectively) can be observed.

Figure 2. Cell viability after exposure to CEES-2
The evaluation of the statistically significant difference
between the averages of the optical density values
correlated with cell viability for the groups intoxicated with
2-chloroethyl-ethyl sulfides and the control group,
performed by applying the T Student test, highlighted the
following aspects presented in Tables 4 and 5.

Table 4. Highlighting the cytotoxicity of the CEES solution 1
No.

Control

1
2

Cells Control
CEES 1 Positive Control

Average optical density CEES Concentration
values (nm)
1,578±0,067
0
0,064 ±0,002
7,78 *10 -2M

P Probability
(T test)

Observations

0,002

< 0,05

Table 5. Highlighting the cytotoxicity of the CEES solution 2
CEES Concentration

P Probability
(T test)

Observations

Cells Control

Average optical density
values (nm)
1,578±0,067

0

0,0035

< 0,05

CEES 2 Positive Control

0,070 ±0,0015

7,78 *10 -3M

No.

Control

1
2
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Optical density correlated with cell viability differs in a
statistically significant way in groups exposed to CEES
concentrations of 7.78 * 10-2 M and 7.78 * 10-3 M and
untreated groups compared to the control cell group. The
evaluation of the statistically significant difference

between the average density values for the groups that were
intoxicated with the two concentrations of 2-chloroethylethyl sulfides and those that received treatment was
performed by applying the Student T test, these aspects
being highlighted in Tables 6 and 7.

Table 6. Comparative cytotoxicity of CEES-1 solution in the absence and in the present of treatment stock solution
No.

Control

Average optical
density values (nm)

CEES
Concentration

Treatment stock solution
(percentage concentration)

1

CEES1 Positive
Control and
treatment

0,823 ± 0,004

7,78 *10 -2M

2

CEES 1 Positive
Control

0,064 ±0,002

7,78 *10 -2M

Acetylcysteine: 10%;
Dexamethasone: 4%;
Ketoprofen: 5%;
0

P Probability
(T test)
0,00039

Observations
<0,05

Table 7. Comparative cytotoxicity of CEES-2 solution in the absence and in the present of treatment stock solution
No.

Control

Average optical
density values (nm)

CEES
Concentration

Treatment stock solution
(dilution)

1

CEES2 Positive
Control and
treatment

0,944 ± 0,0035

7,78 *10 -2M

2

CEES 2 Positive
Control

0,064 ±0,002

7,78 *10 -2M

Acetylcysteine: 10%;
Dexamethasone: 4%;
Ketoprofen: 5%;
0

Optical density correlated with cell viability differs in a
statistically significant manner in the groups exposed to
CEES1 7.78 * 10-2 M and CEES 2 7.78 * 10-3 M
compared to the groups exposed to the same CEES
concentrations and treated with the optimized antidote
stock solution (in a dilution ratio of 1/1). The obtained data
therefore demonstrate the effective therapeutic effect of the
studied antidote in vitro.

P Probability
(T test)
0,00018

Observations
<0,05

Obtaining and characterizing a delivery and controlled
release system for the formulation of an antidote for the
treatment of chemical burns caused by vesicants
Ketoprofen was dosed using the Mediterranean Sea8
chromatographic column (Teknokroma), a column with a
stationary phase of silica gel type modified with C8 groups.
Chromatograms were recorded by measuring the
absorbance at 233 nm (Figures 3 and 4).

Figure 3. Chromatogram obtained for ketoprofen, the associated retention time being 4.902 minutes
wavelength of 244 nm. A calibration curve linear over the
range 4–16 µg/ml was drawn, with these data of the fitting
equation: y = 10.973x + 39.695, R2 = 0.9902 (Figure 5).

Figure 4. Calibration line associated with ketoprofen
Dexamethasone Dosing
The dosing method for dexamethasone in the receptor
liquid was spectrophotometric, implemented using a UVVIS Jasco 650V spectrophotometer. Measurements were
made in quartz cells, reading the maximum absorption at a
298

Figure 5. Calibration curve for dexamethasone
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Study of the release profile of antidote components
Experimental data were used to determine the
cumulative release of the active substances (KET and
DEX), calculated using specialized literature equations.
The total amount of release drug at harvest, expressed as a
percentage of the total amount in the sample that was
subjected to analysis (Figures 6 and 7).

Figure 6. Ketoprofen release profiles from aqueous
antidote solution compared to P6 microemulsion

Figure 7. Dexamethasone release profiles from aqueous
antidote solution compared to P6 microemulsion

Discussion
The main pathogenic mechanism of vesicant
compounds is correlated with their alkylating property [8]
and with their effect on glutathione (GSH), a nucleophilic
antioxidant whose depletion leads to oxidative stress and
macromolecular aggressions [9,10].
Another important pathogenic mechanism is the
activation of some inflammation mediators: prostaglandins
derived from cyclooxygenases [11]. Histopathologically,
vesicant compounds mainly affect the epidermis.
Cytotoxic effects have been observed mainly in basal
keratinocytes (proliferative basal layer). Separation of the
epidermis from the dermis and the appearance of edema
was observed a few hours after exposure. The morphology
of the basal layer was characterized by karyolysis and
pyknosis. The dermis was less affected and showed only
signs of discrete necrosis, along with a low number of
fibroblasts and histiocytes. The erosive areas did not
present an epidermis, but necrosis and massive cellular
infiltration, with a lower degree of leukocyte infiltration
[9,10]. Several studies found that serum levels of

inflammatory mediators such as Il-1, Il6, IL-8, IL-10, IL12, IL-13 mustard vesicants may be correlated with the
severity of lesions induced by vesicants [12]. Interleukin-6
targets multiple cell types and induces a broad array of
responses [13]. IL-6 might be involved in the early event
of structural changes of the signal transducer glycoprotein
that indirectly initiates the cascade of events such as skin
irritation and blister formation observed in the
pathophysiology of HD injury [14]. Exposure to vesicants
can be fatal, especially when pulmonary airways are
affected, causing profound inflammation, hypercoagulation, and oxidative stress. Inflammation can
influence coagulation by increasing cytokine levels of IL6, IL-1, and IL-12, diminishing activated protein C (APC),
decreasing fibrinolysis, and increasing platelet activation
[15-17]. With an interdependent relation between
inflammation and coagulation, the increased cytokine
production led to the expression of the tissue inhibitor of
plasminogen-1, and a tissue factor, and subsequently
triggering the coagulation system through binding to the
clotting factor VIIa [18]. The fluido-coaglant balance is
extremely important in managing inflammation and wound
healing. The inadequate removal of fibrin can hinder the
normal healing process of wounds and may lead to the
formation of fibrous adhesions [19]. Modeling coagulation
and fibrinolysis could be future direction of research in
wound healing [20].
The cutaneous toxic clinical effects of vesicants are
correlated with the absorbed dose and the time of exposure,
appearing late (7-24 hours after exposure) and being
represented by edema, hyperpigmentation and blisters
evolving into phlyctenules [21,22].
The usual medical countermeasures in case of
cutaneous exposure to vesicants mainly involve the
removal of the toxic compound by applying general
decontamination: removal of clothes, thorough rinsing of
the contaminated region with 0.1% benzalkonium bromide
solution, applying antiseptics (silver sulfadiazine) and
local antibiotics, occlusive bandages, and surgical
treatment in case of severe injuries [23-26]. Current studies
indicate that the effect of monotherapy is clearly inferior to
therapies targeted at the multiple pathogenic mechanisms
of vesicants. Thus, it is considered that the antioxidant
antiinflammatory medication, anticytokines, represents a
beneficial alternative in the treatment of this type of lesions
[5,27,28]. In addition, the use of acetylcysteine, sodium
thiosulfate and vitamin E were used in experimental studies
and proved potential benefits due to their antioxidant
properties [29-31]. The treatment of scars is still a
controversial issue, mainly due to unpredictable results.
Therapeutic options include lasers and fractioned radio
frequency [32].
To elucidate pathogenic mechanisms and identify
effective therapeutic solutions, studies were performed
299
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using a chemical vesicant, namely 2-chloroethyl-ethyl
sulfide (CEES) [1,33,34]. It has pathogenic mechanisms
similar to those seen with acute exposure to vesicants
(induction of oxidative stress and inflammatory response),
but is less toxic, constituting a valid experimental
alternative for scientific research studies in the laboratory
[35-37].
By evaluating the experimental data obtained for the
drug release through the skin-like model membrane, we
found that for both tested substances, ketoprofen and
dexamethasone, the transfer is facilitated by their
incorporation in microemulsions. In the case of ketoprofen,
the release occurs with the presence of the initial
acceleration zone from both aqueous solution and
microemulsion. As expected for the chemical structure of
the ketoprofen molecule, very little is released from the
aqueous vehicle, up to a maximum 32%, with the release
occurring rapidly, with the plateau stabilizing after about
8-10 hours. From the microemulsion, it is released
relatively quickly in the first 6 hours, up to approximately
60%, and within 24 hours it is released to up to 79% of the
total amount. For dexamethasone, the release from the
aqueous solution has no acceleration zone and has an
almost linear appearance. A total amount of approximately
50% of what is present in the sample is released after the
first 10 hours from the antidote solution. The amount
released from the microemulsion is significantly higher, up
to 75%, and the transfer through the skin is slightly
prolonged, up to 24 hours.
The novelty element is represented by the therapeutic
association of epidermal growth factors and niacinamidetype Poly (ADP-ribose) polymerase (PARP) inhibitors, as
well as the inclusion of the complex antidote in
microemulsions.
The epidermal growth factor (EGF) family is important
in regulating growth, maturation, function, and
maintenance in epithelial tissues. EGF stimulates the
growth of various epidermal and epithelial tissues in vivo
and in vitro1 and of some fibroblasts in cell culture [10,38]
The EGF family is comprised of 13 members, which are
all membrane-anchored proteins, in addition to their
properties as ligands that activate the epidermal
growth factor receptor (EGFR), bearing tyrosine kinase
activity [39].
The PARP-1 monoclonal antibody recognizes native
and/or cleaved polymerase. PARP cleavage is an early
indicator of apoptosis (the cleaved form of caspase) as well
as of DNA repair. The administration of optimized
complex antidote treatment is correlated with inhibition of
PARP expression, which can be explained by its effect on
maintaining the integrity of the nuclear apparatus, which,
under the protection of the pharmacological agents, is no
longer stimulated to secrete PARP for its repair [40,41].
Microemulsions are the best novel drug delivery
system due to their improved drug solubilization, and ease
300

of preparation and administration [20,27,28,42]. They have
emerged as novel vehicles for drug delivery, which allow
controlled or sustained release for topical, transdermal
administration of drugs [43-45]. Microemulsions are
bicontinuous systems that are essentially composed of bulk
phases of water and oil separated by a surfactant/
cosurfactant-rich interfacial region [46]. With the ability to
carry both lipophilic and hydrophilic drugs, the dispersed
phase, which is lipophilic or hydrophilic (O/W, or W/O
microemulsions), can act as a potential reservoir for
lipophilic or hydrophilic drugs, respectively. The use of
microemulsions as delivery systems can improve the
efficacy of a drug, allowing the total dose to be reduced,
thus minimizing side effects [47].

Conclusions
Optimization of the complex antidote formula was
achieved by developing and in vitro and in vivo testing of
a fixed combination of active substances with antiinflammatory and antioxidant effects, formulated as a
solution with cutaneous administration Also, the complex
antidote was formulated as a gel in 2020. In vitro
cytotoxicity tests on fibroblast cultures revealed the
protective effect of the newly developed antidote solution,
a dose-related effect, in case of exposure to vesicants.
Treatment applied as a 1/1 dilution reduced cytotoxicity for
both CEES formulations.
The complex curative antidote that was developed and
optimized in the study has superior therapeutic efficiency
in case of exposure to sublethal doses of vesicants
simulating mustard gas in experimental conditions. The
novelty element is represented by the realization of a
complex antidote formula, with anti-inflammatory,
antioxidant, healing, hydrating and epithelizing effects
following daily percutaneous administration for 7 days on
the cutaneous chemical burn. Experimental studies have
shown the optimization of transdermal transfer through
encapsulation in microemulsion-type controlled-release
vectors.

Highlights
✓

Chemical burns induced by vesicant agent are severe
and the therapeutic management is challenging.

✓

Using a fixed combination of active substances with
anti-inflammatory and antioxidant effects in a
topically administrated solution revealed a protective
effect on fibroblast cultures exposed to different
concentrations of CEES solution.
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